Developing EZH2-Targeted Therapy for Lung Cancer.

ABSTRACT: Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2. Cancer Discov; 6(9); 949-52. ©2016 AACRSee related article by Zhang and colleagues, p. 1006.

SUBMITTER: Frankel AE 

PROVIDER: S-EPMC5012289 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature